BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zanidatamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zanidatamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06043427-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06043427)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: Paclitaxel and Ramucirumab +/- Z
 anidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06043427
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695845-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06695845)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06695845
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05615818-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT05615818)
DESCRIPTION:Zanidatamab\, phase 3.\nStudy: Personalized Medicine for Advanc
 ed Biliary Cancer Patients\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05615818
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296705-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07296705)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: Neoadjuvant Zanidatamab + Tislel
 izumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive 
 MIBC\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07296705
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A 
 Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy 
 in Participants With HER2-positive Breast Cancer\nEstimated primary comple
 tion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102381
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494448-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zanidatamab: Phase 1/2 readout est. (NCT07494448)
DESCRIPTION:Zanidatamab\, phase 1/2.\nStudy: Phase Ib/II Study of Zanidatam
 ab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07494448
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192068-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07192068)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Trial Evaluating the Activity of Zanidatamab for the Treatment of Pa
 tients With Solid Tumors With an Alteration of the HER2 Gene.\nEstimated p
 rimary completion: 13 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07192068
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Zanidatamab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A 
 Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Ea
 ch in Combination With Physician's Choice Chemotherapy\, for the Treatment
  of Participants With Metastatic HER2-positive Breast Cancer\nEstimated pr
 imary completion: 28 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07477444-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zanidatamab: Phase 1/2 readout est. (NCT07477444)
DESCRIPTION:Zanidatamab\, phase 1/2.\nStudy: Perioperative Zanidatamab and 
 Chemotherapy for HER2 Positive Gastroesophageal Cancer\nEstimated primary 
 completion: June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07477444
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07685704-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07685704)
DESCRIPTION:Zanidatamab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab Com
 bined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positiv
 e (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenoca
 rcinoma: a Phase II Open-Label Study\nEstimated primary completion: June 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07685704
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07290985-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07290985)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: AACR Adaptive Biomarker-Driven O
 rgan Preservation Trial in Gastroesophageal Adenocarcinomas\nEstimated pri
 mary completion: 1 June 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07290985
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07273981-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07273981)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: Zanidatamab Combined With Chemot
 herapy as Neoadjuvant Therapy for HER2-high Expression G/GEJC\nEstimated p
 rimary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07273981
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841873-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07841873)
DESCRIPTION:Zanidatamab\, phase 2\, Biliary Tract Cancer.\nStudy: Zanidatam
 ab Combined With Liposomal Irinotecan and Capecitabine for Second-line Tre
 atment of HER2-positive Unresectable Biliary Tract Tumors\nEstimated prima
 ry completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07841873
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243938-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07243938)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: Phase II Basket Trial: Zanidatam
 ab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)\nEstim
 ated primary completion: 30 July 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07243938
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy 
 and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-o
 f-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated 
 primary completion: 1 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899801-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Zanidatamab: Phase 1 readout est. (NCT07899801)
DESCRIPTION:Zanidatamab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated 
 Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 7 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0789
 9801
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405476-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20281218
DTEND;VALUE=DATE:20281219
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07405476)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: Zanidatamab Before Surgery for t
 he Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned 
 for Curative Intent Treatment\nEstimated primary completion: 18 December 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07405476
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05035836-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT05035836)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: A Phase 2 Single-Arm Open-Label 
 Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER
 2/Neu Positive (HER2+) Breast Cancer (BC)\nEstimated primary completion: 2
 9 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zani
 datamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05035836
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06324357-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:Zanidatamab: Phase 1/2 readout est. (NCT06324357)
DESCRIPTION:Zanidatamab\, phase 1/2.\nStudy: Beamion BCGC-1: A Study to Fin
 d a Suitable Dose of Zongertinib Used Alone and in Combination With Other 
 Treatments to Test Whether it Helps People With Different Types of HER2+ C
 ancer That Has Spread\nEstimated primary completion: 8 January 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/zanidatamab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06324357
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176312-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07176312)
DESCRIPTION:Zanidatamab\, phase 2\, Gastric Cancer.\nStudy: Zanidatamab in 
 Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive
  Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients\nEstimated prim
 ary completion: March 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07176312
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631871-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07631871)
DESCRIPTION:Zanidatamab\, phase 2.\nStudy: An Exploratory Study of Zanidata
 mab in HER2-positive Advanced Tumor After at Least One Line of Standard Th
 erapy\nEstimated primary completion: 31 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07631871
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: I-
 SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Bre
 ast Cancer\nEstimated primary completion: December 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05868226-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Zanidatamab: Phase 1/2 readout est. (NCT05868226)
DESCRIPTION:Zanidatamab\, phase 1/2\, HER2-Positive Breast Cancer.\nStudy: 
 PRE-ISPY Phase I/II Oncology Platform Program\nEstimated primary completio
 n: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05868226
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745296-2201@assetmemo.bio
DTSTAMP:20261121T005640Z
DTSTART;VALUE=DATE:20330702
DTEND;VALUE=DATE:20330703
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT07745296)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Investiga
 ting Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer\nE
 stimated primary completion: 2 July 2033. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07745296
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
